References
- Mullard A . China Biopharma starts feeding global development pipeline. Nat. Rev. Drug Discov.16 (7), 443–446 (2017).
- McKinsey & Company: Building Bridges to Innovation. Shanghai (2017). www.bioindustry.org/uploads/assets/uploaded/62c081ea-59c4-4074-b763be4237988f04.pdf.
- Bristol-Meyers Squibb. China National Drug Administration approves country's first immuno-oncology agent, Opdivo (nivolumab injection), for previously treated non-small cell lung cancer (NSCLC) (2018). https://news.bms.com/press-release/corporatefinancial-news/china-national-drug-administration-approves-countrys-first-imm.
- Dong K , TangD. Bioanalysis outsourcing strategy in China. Bioanalysis9 (15), 1157–1159 (2017).
- CFDA Guidelines for Clinical Trial Bioanalytical Laboratory Management (Interim) (2011). http://www.sda.gov.cn/WS01/CL0844/67395.html.
- 2015 China Pharmacopeia, Guidance for Bioanalytical Method Validation. http://www.drugfuture.com/standard/search.aspx.
- CFDA Announcement of Main Consideration Points for Clinical Data On-site Verification (2015). http://www.sda.gov.cn/WS01/CL0087/172936.html.
- Tang D , ZhongD, DongKet al. Society spotlight: China Bioanalysis Forum. Bioanalysis5 (6), 641–43 (2013).
- Tang D , ZhongD, DongK. Conference Report for 2nd China Bioanalysis Forum Annual Meeting. Bioanalysis6 (20), 2709–2712 (2014).
- Tang D , ZhongD, DongK. The 3rd China Bioanalysis Forum annual meeting. Bioanalysis7 (22), 2853–2856 (2015).
- Tang D , ZhongD, DongK. The 4th China Bioanalysis Forum annual meeting. Bioanalysis9 (2), 159–162 (2016).